The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.2% at $449.52. This change lagged the S&P 500's 1.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.47%, and the ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label expansion and stronger commercial uptake.

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...